SCHEMBL25370930

SCHEMBL25370930

CCCN(CCc1cccs1)[C@H]1CCc2[c]cccc2C1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 9/20 0.65
DRD3 P35462 8/20 0.65
DRD4 P21917 6/20 0.65
HTR1A P08908 2/20 0.65
ADRA2A P08913 1/20 0.65
ADORA3 P0DMS8 1/20 0.65
CHRM1 P11229 1/20 0.65
ADRA2B P18089 1/20 0.65
ADRA2C P18825 1/20 0.65
CNR1 P21554 1/20 0.65
DRD1 P21728 1/20 0.65
ACHE P22303 1/20 0.65
SLC6A2 P23975 1/20 0.65
HTR2A P28223 1/20 0.65
SLC6A4 P31645 1/20 0.65
ADRA1A P35348 1/20 0.65
PTGS2 P35354 1/20 0.65
HRH1 P35367 1/20 0.65
OPRM1 P35372 1/20 0.65
OPRD1 P41143 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25370740 1.00 DRD2 (0.65) DRD2DRD3DRD4HTR1AADRA2A
SCHEMBL15323709 0.84 DRD2 (0.76) DRD2DRD3DRD4HTR1AADRA2A
Rotigotine SCHEMBL50425 0.79 DRD2 (1.00) DRD2DRD3DRD4HTR1AADRA2A
Rotigotine SCHEMBL30200958 0.79 DRD2 (1.00) DRD2DRD3DRD4HTR1AADRA2A
SCHEMBL7333060 0.79 DRD2 (0.77) DRD2DRD3DRD4HTR1AADRA2A
Rotigotine SCHEMBL1088585 0.79 DRD2 (1.00) DRD2DRD3DRD4HTR1AADRA2A
Rotigotine SCHEMBL9405994 0.79 DRD2 (1.00) DRD2DRD3DRD4HTR1AADRA2A
Rotigotine SCHEMBL29354493 0.79 DRD2 (1.00) DRD2DRD3DRD4HTR1AADRA2A
Rotigotine SCHEMBL2597402 0.78 DRD2 (0.98) DRD2DRD3DRD4HTR1AADRA2A
Rotigotine SCHEMBL2597403 0.78 DRD2 (0.98) DRD2DRD3DRD4HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230391744-A1 TETRAHYDRONAPHTHALENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) 2023-12-07 US disclosed
EP-4238966-A1 TETRAHYDRONAPHTHALENE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Guangzhou Henovcom Bioscience Co. Ltd. (CN) 2023-09-06 EP disclosed
CN-114478476-B Tetrahydronaphthalene compounds, pharmaceutical composition and application thereof 广州市恒诺康医药科技有限公司 2023-06-27 CN disclosed
CN-114478476-A Tetrahydronaphthalenes compounds, pharmaceutical compositions and uses thereof 广州市恒诺康医药科技有限公司 2022-05-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391744-A1 TETRAHYDRONAPHTHALENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF CYP11B2, HTT, REN DRD2 769/4885DRD3 222/4885DRD4 1027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.